The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

ADXS-HPV grated orphan drug designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA granted orphan drug designation to ADXS-HPV for the treatment of stage II-IV invasive cervical cancer. ADXS-HPV is an immunotherapy drug candidate, developed by Advaxis Inc., which is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

Scaling excellence: How City of Hope is transforming cancer care delivery

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.
By Alan H. Bryce and Walter M. Stadler
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account